gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE American · TOVXHealthcarePharmaceuticals

Theriva Biologics, Inc. (TOVX)

$0.1900+4.40%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$0.18▼ 44.00% in range
Nov 3, 2025Low $0.17 · High $0.41Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Theriva Biologics closed at $0.19 on Nov 4, up 4.40%, 53.7% below its 52-week closing high. Volume of 1.1M shares was 0.21× its 20-day average (below normal).

Split-adjusted performance: -14.4% over one month, -50.3% over six months, -41.5% over one year.

Short interest was 1.8M shares at the Oct 15 settlement, up 7.8% from the prior report (4.0% of float, 3.3 days to cover).

Market cap$8.7M45.9M shares
Revenue · quarter$0.00—
Diluted EPS$-0.07—
P/E · TTM—P/S 29.1×
Net margin—
Dividend yieldNone$0.0475 last paid
52-week range0.17 – 0.41−53.7% from high
Volume1.1M0.21× 20-day avg
Volatility · 60d51.9%Annualised
Short % of float4.0%3.3 days to cover
Net cash$9.7MCash $11.3M
Next earnings—Not scheduled
Split-adjusted performance
1W +0.1%1M −14.4%3M −15.5%6M −50.3%YTD −9.7%1Y −41.5%3Y −98.3%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum25
Revenue growth—
Net margin—
Value (low P/E)—
Size13

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short1.8M+7.8% vs prior
Days to cover3.3Settled Oct 15
% of float4.0%
Short vol. 10d51.6%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
TOVXTheriva Biologics$0.1900+4.40%−50.3%———$8.7M
GTBPGT Biopharma$4.84−8.16%−51.9%———$8.7MCompare
LTRNLantern Pharma$0.5866−2.61%−72.6%———$8.8MCompare
MBRXMoleculin Biotech$8.46+1.93%−82.9%———$8.6MCompare
MTVAMetaVia$1.34+6.35%−4.3%———$8.8MCompare
LEXXLexaria Bioscience$4.07+0.99%−59.8%−100.0%——$8.6MCompare
ACTUActuate Therapeutics$0.3699+5.69%−87.6%———$8.9MCompare
CURXCuranex Pharmaceuticals$5.80−6.30%−17.7%———$9.1MCompare
CALCCalciMedica$1.35−8.50%−56.8%———$9.2MCompare

News about Theriva Biologics

All news →
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer ResearchGlobeNewswire Inc. · Jun 11, 2026▲ Positive

Quick answers

What does Theriva Biologics do?
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
What is TOVX's market cap?
$8.72M, based on the Nov 4 close of $0.19.
Does Theriva Biologics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of TOVX is sold short?
1.8M shares, 4.0% of float, as of Oct 15, 2026.
What sector is TOVX in?
Healthcare, in the Pharmaceuticals industry.

About Theriva Biologics

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.

HQ: Rockville, MD16 employeesListed Apr 5, 1993therivabio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology